Lenvatinib, a new anticancer agent that acts by inhibiting the expression of VEGFR1-3, FGFR1-4, PDGFRα, SCF, RET and KIT, has been widely used for unresectable or metastatic HCC in China 5. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.